MOTS-c: The Complete Guide
A peptide written into your mitochondrial DNA, released when you exercise, and banned by name in competitive sport. Here is what MOTS-c does, what the research actually shows, and the gap between the two.
This guide summarizes the published research on MOTS-c, including preclinical work, human genetic studies, and the clinical trial of its closest analog. It is educational only and not a substitute for advice from a qualified healthcare professional. Sources are listed at the end.
For most of modern biology, the mitochondrial genome was considered a closed system: thirty-seven genes, all of them dedicated to keeping the cell's energy machinery running. Then in 2015 a team at the University of Southern California found something else hiding in there — a short stretch of code inside the 12S ribosomal RNA gene that produces a sixteen-amino-acid peptide, releases it into the bloodstream, and uses it to send instructions to the rest of the body.
They called it MOTS-c, for mitochondrial open reading frame of the 12S rRNA-c. The finding mattered because it meant mitochondria are not just power plants taking orders from the nucleus. They talk back.
That is a genuinely exciting piece of science, and it is also where the honest version of this page has to start diverging from the marketing version. MOTS-c has an unusually strong biological story and an unusually thin human evidence base. This guide covers both, plus a regulatory detail that matters more for MOTS-c than for almost any other peptide sold as a research compound.
What MOTS-c Is
MOTS-c is a peptide of sixteen amino acids. What makes it unusual is not its size but its address: it is encoded within mitochondrial DNA rather than in the nucleus, where essentially every other signalling peptide in your body originates.
It belongs to a small family called mitochondrial-derived peptides, or MDPs. Humanin was the first to be found, in 2003; MOTS-c followed in 2015; several small humanin-like peptides have been described since. The family is associated with the same research group — Pinchas Cohen's lab at USC — and with a broader idea that mitochondria participate in signalling across the whole organism, not just inside their own cell.
MOTS-c is measurable in human plasma, and two things about those measurements come up repeatedly in the literature. Circulating levels fall with age. And lower levels track with worse metabolic health — MOTS-c is inversely correlated with BMI, fasting insulin, and standard measures of insulin resistance, and it is lower in people with type 2 diabetes.
Correlation is doing a lot of work in that last paragraph
Every one of those observations is cross-sectional. Low MOTS-c in people with metabolic disease could mean the peptide is protective and its loss causes problems. It could equally mean metabolic disease damages mitochondria, which then produce less MOTS-c. The direction of causation has never been established in humans, and it is the single most important open question about this compound.
How MOTS-c Works
The mechanism is one of the more elegant stories in peptide biology, and it converges on AMPK — the enzyme that acts as your cell's fuel gauge. When AMPK switches on, the cell stops storing and starts burning: glucose transporters move to the muscle cell surface, fat oxidation increases, and energy-expensive building programmes get switched off.
Most things that activate AMPK do so by making the cell short of energy. MOTS-c takes a stranger route. It interferes with the folate cycle, which supplies the raw material for building purines from scratch. Blocking that pathway causes an intermediate called AICAR to accumulate inside the cell — and AICAR is itself a natural AMPK activator. The result is AMPK activation without the cell actually running out of fuel.
Simplified from the 2015 discovery paper and subsequent mechanistic work, nearly all of it in rodents and cell culture.
Glucose Uptake
Moves GLUT4 transporters to the muscle cell surface, letting muscle pull glucose out of the blood without needing more insulin to do it.
Fat Oxidation
Downstream of AMPK, cells shift toward burning fatty acids. In mice this reduced fat mass without the animals eating less.
Nuclear Signalling
Under metabolic stress MOTS-c enters the nucleus and regulates stress-response and antioxidant genes — mitochondria issuing instructions to the nuclear genome.
Mitochondrial Biogenesis
Increases expression of genes that build new mitochondria, one of the adaptations endurance training normally produces.
What the Research Shows
What is well established — in animals and cells
The preclinical record is consistent and, on its own terms, impressive. In the original 2015 work, mice on a high-fat diet given MOTS-c were protected from diet-induced obesity and insulin resistance. The effect did not come from appetite suppression: the animals ate normally and still put on less fat. Later studies added improvements in glucose tolerance, reduced fat accumulation in the liver, lower inflammatory markers in obese models, and increases in markers of mitochondrial density in muscle.
None of that is in dispute. What is in dispute is whether any of it transfers to a person injecting a research peptide under their skin.
What humans actually show
There is human data on MOTS-c. It is just not the kind most people assume. The strongest evidence comes from genetics rather than from anyone being given the peptide.
A mitochondrial variant found almost exclusively in Northeast Asian populations, m.1382A>C, swaps a single amino acid in MOTS-c and produces a partially inactive version of the peptide. A meta-analysis pooling three cohorts totalling more than 27,000 people found that men carrying this variant had a higher prevalence of type 2 diabetes. Women did not. And the effect concentrated in the least physically active men — carriers who exercised showed much less of it.
Why the genetics matter more than they look
That finding is close to a natural experiment. People who inherit a weaker version of MOTS-c have measurably worse metabolic outcomes, which is real evidence that MOTS-c does something meaningful in human physiology. It is not evidence that injecting extra MOTS-c improves anything in someone whose own version works fine. Those are different claims, and only the first one has human support.
The Exercise Connection
The most cited MOTS-c finding after the original discovery came in 2021. Researchers showed that in humans, exercise sharply raises MOTS-c: levels in skeletal muscle rose roughly twelve-fold after a bout of exercise and remained partly elevated hours later, while circulating levels rose by about half.
The same paper gave MOTS-c to mice at three ages — young, middle-aged and old — and found improved physical performance in all three groups. Treatment started late in life, three times a week, improved physical capacity and measures of healthspan.
This is where the phrase "exercise mimetic" entered the MOTS-c conversation, and it is worth handling carefully. The human half of that study showed MOTS-c is released by exercise. The mouse half showed that giving MOTS-c improves performance. Neither showed that injecting MOTS-c substitutes for training in a person. The most defensible reading is that MOTS-c is part of the machinery through which exercise produces its benefits — which, if anything, is an argument for training, not a replacement for it.
The One Human Trial
MOTS-c itself has never been through a published clinical trial. Its closest analog has, and the story is instructive.
A biotech company co-founded by the peptide's discoverer developed CB4211, a modified version of MOTS-c designed to have better drug-like properties than the natural peptide. It went into a Phase 1a/1b study for fatty liver disease and obesity — the first mitochondrial-derived peptide ever tested in humans.
The Phase 1a stage tested safety in 65 healthy adults. The Phase 1b stage was randomised, double-blind and placebo-controlled: twenty obese participants with at least 10% liver fat, given 25 mg by subcutaneous injection daily for four weeks. Topline results in August 2021 reported the drug was well tolerated with no serious adverse events, alongside significant reductions in the liver enzymes ALT and AST, a significant fall in glucose, and a trend toward lower body weight.
Those are encouraging exploratory findings in twenty people over four weeks. What happened next is the part usually left out. The company later stated that the formulation used in the Phase 1b stage was not suitable for further development, that efforts to produce an improved formulation had not succeeded, and that it was seeking a partner for the programme. In 2023 the company merged into an oncology business and the mitochondrial peptide pipeline was not carried forward. CB4211 has not advanced since.
One claim to be sceptical of
Several websites state that MOTS-c has completed a Phase 1 human safety study at doses up to 10 mg. That appears to be a garbled account of the CB4211 trial, which tested a different molecule at 25 mg. No published clinical trial has ever administered MOTS-c itself to humans, and no human pharmacokinetic data for it exists. If a source tells you otherwise, check what compound it is actually describing.
Dosing in the Research
Because no human trial of MOTS-c exists, there is no dose that has ever been validated in a person. What circulates instead is a convention, and it is worth seeing where that convention came from.
| Source | Dose | Route | What it tells you |
|---|---|---|---|
| Original 2015 mouse work | Roughly 0.5–15 mg/kg depending on the experiment | Intraperitoneal | Where the whole field starts; a route not used in people |
| 2021 aged-mouse study | High mg/kg range, three times weekly | Intraperitoneal | The origin of the 3×/week rhythm people use |
| CB4211 Phase 1b (an analog) | 25 mg once daily, 4 weeks | Subcutaneous | The only human dosing data — for a different molecule |
| Community protocol convention | 5–10 mg per injection, 2–3× weekly | Subcutaneous | Not derived from any trial in humans or animals |
Scaling animal doses to humans is done with a standard body-surface-area conversion, which for mouse to human divides by roughly twelve. Run it and the numbers are striking. A 5 mg/kg mouse dose scales to about 28 mg for a 70 kg adult. A 15 mg/kg mouse dose scales to about 85 mg. The 5–10 mg figure people actually use sits well below both.
Whether the common dose reflects sensible caution or is simply too low to do anything is not known. No study has compared them in people.
That gap is the honest headline for MOTS-c dosing. The schedule people follow was inherited from a mouse study; the amount was not. Neither has been tested in a human.
Side Effects & Safety
There is no clinical safety database for MOTS-c. The analog trial found its 25 mg dose well tolerated over four weeks in twenty people, with injection-site reactions the notable issue, and that is the entirety of the controlled human safety record for anything in this class.
What users report
Drawing on self-experimenter reports rather than trials, the commonly described effects are increased heart rate or palpitations, injection-site irritation, insomnia, and fever. None of this has been characterised systematically, and none of it should be read as a complete list.
Three situations that deserve specific caution
If you take metformin, insulin, or a sulfonylurea. MOTS-c works by activating AMPK — the same broad territory metformin operates in — and by increasing glucose uptake into muscle. Stacking it with glucose-lowering medication has never been studied and creates a plausible route to hypoglycaemia. This is the interaction most worth taking seriously. If you have a cardiac arrhythmia or structural heart disease. Palpitations and raised heart rate are among the most commonly reported effects, and AMPK activation affects how cardiac tissue handles energy. If you have or have had cancer. AMPK activation and antioxidant gene regulation both intersect with tumour biology in ways that cut in more than one direction, and the net effect has not been studied. No data exists for pregnancy or breastfeeding either.
Competitive athletes: read this twice
MOTS-c is named explicitly on the WADA Prohibited List. It appears under hormone and metabolic modulators, in the AMPK activator subcategory, alongside AICAR — spelled out in full as "mitochondrial open reading frame of the 12S rRNA-c (MOTS-c)". It is prohibited at all times, in and out of competition.
This is not the usual situation where a research peptide gets swept up by a catch-all clause. WADA went to the trouble of naming this specific molecule. Several peptide sites state that MOTS-c is not on the list; they are wrong, and an athlete relying on that would be relying on a factual error. If you are subject to anti-doping testing, treat MOTS-c as a prohibited substance and confirm the current position with your national anti-doping organisation.
How MOTS-c Compares
MOTS-c gets grouped with several very different compounds. The distinctions are worth keeping straight.
| Compound | How it works | Human evidence | WADA status |
|---|---|---|---|
| MOTS-c | AMPK activation via the folate cycle and AICAR | Genetic and observational only; no interventional trial | Named explicitly; prohibited at all times |
| AICAR | Direct AMP mimetic; activates AMPK directly | Large cardiac surgery trials; never approved | Named explicitly; prohibited since 2009 |
| SLU-PP-332 | ERR agonist; endurance programme without AMPK | Rodent only | Not named; treat as prohibited |
| GLP-1 drugs | Appetite and gastric emptying | Large phase 3 trials; approved | Not prohibited |
| SS-31 | Binds cardiolipin in the mitochondrial membrane | Phase 2/3 trials; mixed results | Not named |
The most important comparison is the one not in the table. If your goal is better insulin sensitivity, more mitochondria, and improved metabolic flexibility, resistance training plus zone-two cardio produces all three, has the strongest evidence base of anything on this page, and is the intervention that raises your own MOTS-c twelve-fold. Nothing here substitutes for that.
Where MOTS-c Stands Legally
MOTS-c is not approved as a finished pharmaceutical drug by the FDA, the EMA, or Costa Rica's Ministerio de Salud. It is sold as a research compound. Two recent developments are worth knowing about.
- 2023 — the FDA placed MOTS-c, along with a group of other peptides, in Category 2 of its 503A bulk drug substances list, blocking compounding pharmacies from preparing it.
- April 2026 — the FDA removed twelve substances, MOTS-c among them, from Category 2 for further evaluation.
- July 2026 — the Pharmacy Compounding Advisory Committee reviewed seven peptides. MOTS-c was among the six recommended for the 503A Bulks List, on a narrow vote and over the objection of the FDA's own scientific reviewers.
It is easy to over-read that vote. It is advisory and non-binding; the FDA still has to run a separate rulemaking process that typically takes a year or more; and nothing about the compound's legal status has changed as a result. It is also not a statement that the evidence is strong — FDA staff had recommended against listing all seven, citing thin data. What the vote reflects is a policy shift toward access, not a new body of research.
None of this affects sport. A favourable compounding recommendation and a WADA prohibition are entirely separate systems, and the WADA position on MOTS-c has not moved. Our guide to research peptides versus pharmaceutical peptides explains what "research compound" means in practice for quality and oversight.
Common Questions
Does MOTS-c actually work in humans?
Nobody knows, because it has never been tested. The animal data is strong and consistent, the human genetic data suggests the peptide matters in our physiology, and the analog trial produced encouraging four-week biomarker changes in twenty people. That is a reasonable basis for interest and not a basis for confidence.
Is MOTS-c a weight-loss peptide?
It is studied in a different way from the GLP-1 compounds. Those work substantially through appetite — you eat less, so you lose weight. In mice, MOTS-c reduced fat mass without reducing food intake, by shifting how fuel is used rather than how much is eaten. Whether that translates to meaningful weight change in a person is untested. If weight loss is the goal, see our guide on how GLP-1 peptides work for the compounds that do have trial data.
Can I take MOTS-c with metformin or berberine?
This is the combination question that deserves a real answer rather than a shrug. Both metformin and MOTS-c push on AMPK signalling and glucose handling, and stacking two agents with overlapping effects on blood glucose without any study of the combination is how people end up hypoglycaemic. Anyone on glucose-lowering medication should be talking to the doctor who prescribed it before adding anything. See also our overview of peptide drug interactions.
Will MOTS-c make me fail a drug test?
If you are tested under the WADA code, yes — that is the entire point of it being on the list by name. It is prohibited in and out of competition. Recreational lifters not subject to anti-doping rules are not affected by WADA, but anyone in a tested sport, including many amateur and masters competitions, should treat this as disqualifying.
Does MOTS-c replace cardio?
No, and the research points the other way. The human finding was that exercise produces MOTS-c — a roughly twelve-fold rise in muscle. The mouse findings suggest it may be one of the messengers exercise uses. The most sensible reading is that MOTS-c is downstream of training, so training is the thing with the evidence behind it.
How long until I notice anything?
There is no published human timeline, so any specific answer would be invented. In the analog trial, biomarker changes were measured at four weeks. Since the effects being studied are metabolic rather than sensory, there may be nothing to feel at all — which makes bloodwork more informative than subjective impressions if you are working with a clinician.
Should MOTS-c be cycled?
Cycling schedules for MOTS-c come from general peptide convention rather than from any receptor-downregulation data specific to this compound. The three-times-weekly rhythm most protocols use was inherited from a mouse study design, not from a finding about tolerance. It is fair to say the schedules are plausible; it is not fair to say they are evidence-based.
How is MOTS-c stored and reconstituted?
Sealed lyophilized vials keep frozen and protected from light; once reconstituted, the solution stays refrigerated at 2–8°C. MOTS-c dissolves readily in bacteriostatic water with no special solvent needed. Our guides on reconstitution and storing peptides in tropical climates cover the practical side, which matters more here than in temperate countries.
What sizes does Peptides Costa Rica stock, and what does MOTS-c cost?
MOTS-c is listed in 10 mg and 40 mg vials. Current pricing and live stock are on the MOTS-C product page, and five or more vials of the same product carry an automatic 15% discount. Message us if you want a stock check before ordering.
Is MOTS-c legal in Costa Rica?
It is sold here as a research compound, the same framework used in most countries with an active peptide market, and is not approved as a finished pharmaceutical drug by the Ministerio de Salud, the FDA or the EMA. Our FAQ page covers ordering and delivery within Costa Rica.
Questions about MOTS-c?
Happy to talk through what the research supports and what it doesn't — including whether this is the right compound for what you are trying to achieve, or whether something with more human data would serve you better.
Contact Us on WhatsAppImportant disclaimer: The information in this guide is general educational content only. It is not medical advice, a prescription, or a personalized recommendation. MOTS-c is not approved by the FDA, the EMA, or Costa Rica's Ministerio de Salud as a finished pharmaceutical drug for human use, and is sold as a research compound intended for laboratory and scientific study. In July 2026 the FDA's Pharmacy Compounding Advisory Committee recommended MOTS-c for inclusion on the 503A Bulks List; that recommendation is advisory, non-binding, and does not change the compound's legal status or make it an approved medicine. It is not a treatment for obesity, type 2 diabetes, insulin resistance, fatty liver disease, or any other condition. No clinical trial of MOTS-c in humans has been published and no human pharmacokinetic data exists; the efficacy evidence described here comes from rodent and cell studies, from human observational and genetic research, and from a four-week Phase 1b study of CB4211, a different molecule. Dosing ranges discussed reflect what is reported in published animal research and community use; they are not endorsements of those doses for any specific individual, and no dose has been validated in a person. MOTS-c activates AMPK and increases glucose uptake, creating a plausible risk of hypoglycaemia in combination with metformin, insulin, sulfonylureas or other glucose-lowering agents; no interaction studies exist. Reported effects include increased heart rate and palpitations. No safety data exists for pregnancy, breastfeeding, or long-term use, and the effect on tumour biology has not been studied. MOTS-c is named explicitly on the WADA Prohibited List under hormone and metabolic modulators and is prohibited at all times, in and out of competition. Always consult a qualified healthcare professional before beginning any peptide protocol. Products sold by Peptides Costa Rica are intended for laboratory and research purposes only.
- Cell Metabolism (Lee et al., 2015): The discovery paper identifying MOTS-c within the mitochondrial 12S rRNA and describing folate-cycle inhibition, AICAR accumulation and AMPK activation in skeletal muscle.
- Nature Communications (Reynolds et al., 2021): Exercise induces MOTS-c in human skeletal muscle and circulation; MOTS-c treatment improved physical capacity in young, middle-aged and old mice.
- Aging (Zempo, Kim, Cohen et al., 2021): Meta-analysis of three cohorts totalling over 27,000 people linking the m.1382A>C variant and the K14Q form of MOTS-c to type 2 diabetes risk in men, with an interaction with physical activity.
- Journal of Clinical Investigation (Miller, Kim, Kumagai, Yen & Cohen, 2022): Review of mitochondrial-derived peptides in aging, including the decline of circulating MOTS-c with age and its inverse relationship with BMI and insulin resistance.
- Cell Metabolism (Kim et al., 2018): Demonstration that MOTS-c translocates to the nucleus under metabolic stress and regulates nuclear gene expression.
- CohBar, Inc. corporate disclosures and SEC filings (2021–2023): Phase 1a/1b topline results for the MOTS-c analog CB4211, and the subsequent statement that the formulation used was unsuitable for further development.
- ClinicalTrials.gov (NCT03998514): Registration details for the CB4211 Phase 1a/1b study in obese participants with fatty liver disease.
- World Anti-Doping Agency: Prohibited List, hormone and metabolic modulators, naming MOTS-c among prohibited AMPK activators.
- U.S. Anti-Doping Agency: Athlete guidance on AICAR and other prohibited AMPK activators, and on reported adverse effects of MOTS-c self-experimentation.
- U.S. Food and Drug Administration: 503A bulk drug substances list and the July 2026 Pharmacy Compounding Advisory Committee proceedings.
